BAT6026

Overview

BAT6026 is an agonist monoclonal antibody targeting OX40 (TNFRSF4), a T-cell co-stimulatory receptor. It is designed to enhance anti-tumor T-cell responses. BAT6026 was in phase I investigation in solid tumors including NPC; no significant NPC-specific activity has been reported to date.

Evidence in the corpus

• Cited among investigational OX40 agonists in phase I for NPC; no significant NPC activity reported PMID:24952746.

Resistance mechanisms

Cancer types (linked)

• NPC

Sources

This page was processed by entity-page-writer on 2026-05-11.